Guggenheim Issues Pessimistic Forecast for Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price

Adaptimmune Therapeutics (NASDAQ:ADAP) had its target price decreased by Guggenheim from $4.00 to $3.00 in a research report report published on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also commented on ADAP. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. HC Wainwright decreased their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a report on Thursday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Trading Down 0.8 %

Shares of ADAP opened at $0.59 on Friday. The stock has a market capitalization of $150.02 million, a P/E ratio of -2.67 and a beta of 2.26. The firm has a fifty day simple moving average of $0.88 and a two-hundred day simple moving average of $1.03. The company has a quick ratio of 3.09, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a twelve month low of $0.42 and a twelve month high of $2.05.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently made changes to their positions in the company. Vontobel Holding Ltd. grew its position in shares of Adaptimmune Therapeutics by 230.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after buying an additional 30,000 shares during the period. Fullcircle Wealth LLC purchased a new stake in shares of Adaptimmune Therapeutics in the 3rd quarter worth approximately $33,000. FMR LLC increased its position in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after buying an additional 50,419 shares in the last quarter. Boulder Hill Capital Management LP bought a new position in shares of Adaptimmune Therapeutics during the first quarter valued at $143,000. Finally, Jane Street Group LLC boosted its stake in Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares in the last quarter. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.